Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial
Quantum BioPharma receives FDA clearance for Phase 2 trial of Lucid-MS, a first-in-class drug for progressive MS that may repair myelin, offering new hope.
This news matters because it represents a potential breakthrough in the treatment of progressive multiple sclerosis, a condition with few effective options. If Lucid-MS proves successful, it could not only slow the disease but also repair damage, improving quality of life for millions. It also underscores the importance of innovative approaches in tackling neurodegenerative diseases, offering hope where current therapies fall short.
